BioAtla Investor Presentation Deck

Phase 2 study design with BA3011 (Mecbotamab Vedotin) in refractory NSCLC patients Interim analysis AXL+ ≥1 TmPS Monotherapy and in Combination with PD-1/L1 All patients refractory to PD-1/L1, EGFR and / or ALK inhibitors Use to determine TmPS cut- off and P2, part 2 dose Next step Applying exposure-response learnings Request FDA feedback re: Phase 2, part 2 Complete interim analysis* and select Phase 2, part 2 conditions Following FDA feedback, initiate Phase 2, part 2 (potentially registrational trial) *To be presented at a medical meeting. Phase 2, part 2 bicatla progression-free survival; SAE, serious adverse event; TTR, time to response. Monotherapy (BA3011), PD-1 failure NSQ NSCLC Potentially registrational Phase 2, part 2 patient number TBD pending discussion with FDA Endpoints Primary endpoints Confirmed ORR per RECIST v1.1 AES or SAEs Secondary endpoints DOR, PFS, ORR, DCR, TTR, OS NSQ, nonsquamous; AE, adverse event; BOR, best overall response; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, BioAtla| Overview 18

View entire presentation